Skip to main content
Top
Published in: Critical Care 2/2002

01-04-2002 | Commentary

Coagulation cascade in sepsis: getting from bench to bedside?

Published in: Critical Care | Issue 2/2002

Login to get access

Abstract

The relationship between blood coagulation factors and the promotion or inhibition of the anti-inflammatory response continues to be defined through basic research. The potential key role of blood coagulation factors in the response during sepsis provides an exciting potential mechanism(s) for modification through the application of new therapies. The complexity of the potential multiple actions of the proteins, such as protein C, should allow for development of new therapies to minimize the detrimental inflammatory response. However, several gaps in our current understanding must be bridged before the clinician can take the basic knowledge 'to the bedside', where individual patients will benefit.
Literature
2.
go back to reference Marshall JC: Modulation of the systemic inflammatory response in sepsis: current status, future prospects. Crit Care Rounds 2001, 2: 1-6. Marshall JC: Modulation of the systemic inflammatory response in sepsis: current status, future prospects. Crit Care Rounds 2001, 2: 1-6.
3.
go back to reference Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr, Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Eng J Med 2001, 344: 699-709. 10.1056/NEJM200103083441001CrossRef Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr, Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Eng J Med 2001, 344: 699-709. 10.1056/NEJM200103083441001CrossRef
4.
go back to reference DePalo V, Kessler C, Opal SM: Success or failure in phase III sepsis trials: Comparison between drotrecogin alfa (activated) and antithromin III clinical trials. Adv Sepsis 2001, 1: 144-124. DePalo V, Kessler C, Opal SM: Success or failure in phase III sepsis trials: Comparison between drotrecogin alfa (activated) and antithromin III clinical trials. Adv Sepsis 2001, 1: 144-124.
5.
go back to reference Healy DP: New and emerging therapies for sepsis. Ann Pharmacother 2002, 36: 648-654. 10.1345/1542-6270(2002)036<0648:NAETFS>2.0.CO;2CrossRefPubMed Healy DP: New and emerging therapies for sepsis. Ann Pharmacother 2002, 36: 648-654. 10.1345/1542-6270(2002)036<0648:NAETFS>2.0.CO;2CrossRefPubMed
6.
go back to reference Vincent JL, Wun Q, Dubois MJ: Clinical trials of immunodulatory therapies in severe sepsis and septic shock. Clin Infect Dis 2002, 34: 1084-1093. 10.1086/339549CrossRefPubMed Vincent JL, Wun Q, Dubois MJ: Clinical trials of immunodulatory therapies in severe sepsis and septic shock. Clin Infect Dis 2002, 34: 1084-1093. 10.1086/339549CrossRefPubMed
Metadata
Title
Coagulation cascade in sepsis: getting from bench to bedside?
Publication date
01-04-2002
Published in
Critical Care / Issue 2/2002
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/cc1842

Other articles of this Issue 2/2002

Critical Care 2/2002 Go to the issue